DE60120109D1 - Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin - Google Patents

Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin

Info

Publication number
DE60120109D1
DE60120109D1 DE60120109T DE60120109T DE60120109D1 DE 60120109 D1 DE60120109 D1 DE 60120109D1 DE 60120109 T DE60120109 T DE 60120109T DE 60120109 T DE60120109 T DE 60120109T DE 60120109 D1 DE60120109 D1 DE 60120109D1
Authority
DE
Germany
Prior art keywords
didesmethylsibutramine
optic
pure
preparation
racemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60120109T
Other languages
English (en)
Other versions
DE60120109T2 (de
Inventor
H Senanayake
K Fang
Zhengxu Han
Dhileepkumar Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of DE60120109D1 publication Critical patent/DE60120109D1/de
Application granted granted Critical
Publication of DE60120109T2 publication Critical patent/DE60120109T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/18—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/457—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60120109T 2000-01-11 2001-01-10 Verfahren zur herstellung von optisch reinem (r)- und (s)- didesmethylsibutramin Expired - Fee Related DE60120109T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/480,889 US6399826B1 (en) 1999-08-11 2000-01-11 Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US480889 2000-01-11
PCT/US2001/000762 WO2001051453A1 (en) 2000-01-11 2001-01-10 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors

Publications (2)

Publication Number Publication Date
DE60120109D1 true DE60120109D1 (de) 2006-07-06
DE60120109T2 DE60120109T2 (de) 2006-10-19

Family

ID=23909753

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120109T Expired - Fee Related DE60120109T2 (de) 2000-01-11 2001-01-10 Verfahren zur herstellung von optisch reinem (r)- und (s)- didesmethylsibutramin

Country Status (12)

Country Link
US (2) US6399826B1 (de)
EP (2) EP1632471A1 (de)
JP (1) JP2003519675A (de)
AT (1) ATE327972T1 (de)
AU (1) AU782567B2 (de)
CA (1) CA2396950A1 (de)
CY (1) CY1106150T1 (de)
DE (1) DE60120109T2 (de)
DK (1) DK1246789T3 (de)
ES (1) ES2260195T3 (de)
PT (1) PT1246789E (de)
WO (1) WO2001051453A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
MXPA03004288A (es) * 2000-11-15 2004-09-10 Tap Pharmaceutical Prod Inc Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7129378B2 (en) * 2002-04-10 2006-10-31 Apsinterm, Llc Method of preparing amine stereoisomers
PL375032A1 (en) * 2002-10-05 2005-11-14 Hanmi Pharm.Co, Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
WO2005041988A1 (en) * 2003-10-22 2005-05-12 University Of Florida Method and composition for pain amelioration
US20050209220A1 (en) * 2004-03-19 2005-09-22 Jeffrey Conforti Treatment of peripheral neuropathy
JP2008527035A (ja) 2005-01-18 2008-07-24 ユニヴァーシテイ オブ フロリダ 疼痛を抑制するための組成物及び方法
US20060160905A1 (en) * 2005-01-18 2006-07-20 Bergeron Raymond J Jr Compositions and methods for inhibiting pain
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN101555214B (zh) * 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
WO2010065889A2 (en) * 2008-12-06 2010-06-10 Auspex Pharmaceutical Cyclobutanemethanamine inhibitors of monomine reuptake
US9119843B2 (en) * 2009-12-04 2015-09-01 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина
GB202114564D0 (en) * 2021-10-12 2021-11-24 Actimed Therapeutics Ltd Oral formulation

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (de) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
JPS5940638A (ja) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd 直接ポジ用ハロゲン化銀写真乳剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69318196T2 (de) 1992-01-28 1998-08-27 Fujitsu Ltd Plasma Farbanzeige-Vorrichtung von Oberflächenentladungs-Typ
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
WO1994000047A1 (en) 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
JPH08500093A (ja) 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
WO1996009069A1 (fr) 1994-09-19 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation medicale d'un antagoniste de 5ht¿3?
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
GB2340037A (en) 1998-07-30 2000-02-16 Glaxo Group Ltd Compositions comprising bupropion for the treatment of premature ejaculation
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6346549B1 (en) 1999-03-19 2002-02-12 Knoll Pharmaceutical Company Treatment of pharmacology of drug misuse and other addictive disorders
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
WO2000056318A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
EP1178790A1 (de) 1999-03-19 2002-02-13 Knoll GmbH Behandlung zur verminderung des adhäsionsvermögens von plättchen
WO2000056306A1 (en) 1999-03-19 2000-09-28 Knoll Gmbh Treatment of osteoarthritis
AU3757300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating anxiety disorders
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
AU3899100A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3898600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating obsessive-compulsive disorder
AU3759800A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of premenstrual syndrome
WO2000056320A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of menstrual function
SI1169029T1 (sl) 1999-03-19 2005-12-31 Abbott Gmbh & Co Kg Uporaba sibutramina ali njegova derivata za zdravljenje motenj med spanjem
DE60039508D1 (de) 1999-03-19 2008-08-28 Abbott Gmbh & Co Kg Methoden zur behandlung der essstörungen
GB9914742D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
US20020183281A1 (en) 2002-12-05
PT1246789E (pt) 2006-10-31
EP1246789A1 (de) 2002-10-09
JP2003519675A (ja) 2003-06-24
CY1106150T1 (el) 2011-06-08
US6399826B1 (en) 2002-06-04
WO2001051453A1 (en) 2001-07-19
ATE327972T1 (de) 2006-06-15
CA2396950A1 (en) 2001-07-19
US6710087B2 (en) 2004-03-23
AU2779301A (en) 2001-07-24
DE60120109T2 (de) 2006-10-19
EP1632471A1 (de) 2006-03-08
ES2260195T3 (es) 2006-11-01
DK1246789T3 (da) 2006-09-18
AU782567B2 (en) 2005-08-11
EP1246789B1 (de) 2006-05-31

Similar Documents

Publication Publication Date Title
DE60120109D1 (de) Verfahren zur herstellung von optisch-reinen (r)- und (s)- didesmethylsibutramin
NO2020010I1 (no) fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
HUP0300301A2 (hu) Új (amino-propil)-metil-foszfinsavak
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
DE602005027540D1 (de) Feste formulierungen von ospemifen
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
CY1106682T1 (el) Ενωση λακταμης
ATE308522T1 (de) Opioidrezeptorantagonisten
DE602004005323D1 (de) Azidfreies verfahren zur herstellung von 1,2-diaminoverbindungen
BR0315574A (pt) Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
BR0209554A (pt) Métodos para a preparação de um composto, e composto
NO20041059L (no) Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
MY138826A (en) 2,7-substituted indoles
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
ATE469887T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
NZ512684A (en) Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee